Does hand stiffness reflect internal organ fibrosis in diabetes mellitus?

dc.contributor.author

Phatak, Sanat

dc.contributor.author

Ingram, Jennifer L

dc.contributor.author

Goel, Pranay

dc.contributor.author

Rath, Satyajit

dc.contributor.author

Yajnik, Chittaranjan

dc.date.accessioned

2023-08-01T13:30:58Z

dc.date.available

2023-08-01T13:30:58Z

dc.date.issued

2023-01

dc.date.updated

2023-08-01T13:30:57Z

dc.description.abstract

Fibrosis leads to irreversible stiffening of tissue and loss of function, and is a common pathway leading to morbidity and mortality in chronic disease. Diabetes mellitus (both type 1 and type 2 diabetes) are associated with significant fibrosis in internal organs, chiefly the kidney and heart, but also lung, liver and adipose tissue. Diabetes is also associated with the diabetic cheirarthropathies, a collection of clinical manifestations affecting the hand that include limited joint mobility (LJM), flexor tenosynovitis, Duypuytren disease and carpal tunnel syndrome. Histo-morphologically these are profibrotic conditions affecting various soft tissue components in the hand. We hypothesize that these hand manifestations reflect a systemic profibrotic state, and are potential clinical biomarkers of current or future internal organ fibrosis. Epidemiologically, there is evidence that fibrosis in one organ associates with fibrosis with another; the putative exposures that lead to fibrosis in diabetes (advanced glycation end product deposition, microvascular disease and hypoxia, persistent innate inflammation) are 'systemic'; a common genetic susceptibility to fibrosis has also been hinted at. These data suggest that a subset of the diabetic population is susceptible to multi-organ fibrosis. The hand is an attractive biomarker to clinically detect this susceptibility, owing to its accessibility to physical examination and exposure to repeated mechanical stresses. Testing the hypothesis has a few pre-requisites: being able to measure hand fibrosis in the hand, using clinical scores or imaging based scores, which will facilitate looking for associations with internal organ fibrosis using validated methodologies for each. Longitudinal studies would be essential in delineating fibrosis trajectories in those with hand manifestations. Since therapies reversing fibrosis are few, the onus lies on identification of a susceptible subset for preventative measures. If systematically validated, clinical hand examination could provide a low-cost, universally accessible and easily reproducible screening step in selecting patients for clinical trials for fibrosis in diabetes.

dc.identifier.issn

2673-6616

dc.identifier.issn

2673-6616

dc.identifier.uri

https://hdl.handle.net/10161/28575

dc.language

eng

dc.publisher

Frontiers Media SA

dc.relation.ispartof

Frontiers in clinical diabetes and healthcare

dc.relation.isversionof

10.3389/fcdhc.2023.1198782

dc.subject

diabetic cheiroarthropathy

dc.subject

fibrosis

dc.subject

hand - pathology

dc.subject

joint stiffness

dc.subject

multi-organ

dc.title

Does hand stiffness reflect internal organ fibrosis in diabetes mellitus?

dc.type

Journal article

duke.contributor.orcid

Ingram, Jennifer L|0000-0002-5269-8864

pubs.begin-page

1198782

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Medicine

pubs.organisational-group

Pathology

pubs.organisational-group

Surgery

pubs.organisational-group

Medicine, Pulmonary, Allergy, and Critical Care Medicine

pubs.organisational-group

Surgery, Surgical Sciences

pubs.publication-status

Published

pubs.volume

4

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Phatak Frontiers_hypothesisarticle.pdf
Size:
678.76 KB
Format:
Adobe Portable Document Format
Description:
Published version